Posted February 9, 2007
DURHAM, N.C. – Argos Therapeutics is launching a clinical trial for its proposed HIV treatment that is designed to help a patient’s immune system defeat the AIDS virus.
The trial is designed to test the activity and safety of the AGS-004 compound.
Ten HIV-infected adults will receive the treatment, which is personalized and based on RNA. It utilizes dendritic cells, which are part of the human immune system.
“A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient,” said Jean-Pierre Routy, M.D., of McGill University Health Center and Royal Victoria Hospital. He is the principle investigator and sponsor of the study. “This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.” Copyright 2012 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Argos To Launch HIV Treatment Trial on Infected Adults
Post a comment
Print this storyE-mail story
Share
The trial is designed to test the activity and safety of the AGS-004 compound.
Ten HIV-infected adults will receive the treatment, which is personalized and based on RNA. It utilizes dendritic cells, which are part of the human immune system.
“A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient,” said Jean-Pierre Routy, M.D., of McGill University Health Center and Royal Victoria Hospital. He is the principle investigator and sponsor of the study. “This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.” Copyright 2012 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
